CLERKENWELL, U.K. - TelAve -- PRESS RELEASE

General Media  |  Embargoed to May 7, 2026

New platform launches to close the gap between drug approval and patient access

London, UK – May 7, 2026 – BrandLaunchX, an AI-powered platform for biotech and pharmaceutical launch navigation, launches today. The company was founded after its CEO, Abhijit Sengupta, lost a loved one to illness despite effective treatments being available. The drugs existed. They had been approved. But the launch had not reached the markets where they were needed.

Sengupta spent two decades as a senior executive at AstraZeneca and Novartis, watching the same pattern repeat. Up to 80% of new therapeutic launches underperform expectations, not because the science fails but because coordinating 12 to 16 specialist teams across multiple territories, evidence requirements, payer negotiations and commercial timelines overwhelms the tools most organisations are using. Single-day launch delays can cost companies up to $16 million. The consequences for patients are longer waits for therapies that already exist.

More on TelAve News

• UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
• Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
• June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
• Phinge Home Of Netverse, Is Actively Investigating The "Model Context Protocol" (MCP) For Infringement Of Its IP From Its June, 2021 Priority Dates
• Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules

"Behind every launch delay is a patient who could benefit from a therapy that already exists but cannot access it because of coordination failures they will never even know about."

- Abhijit Sengupta, Founder and CEO, BrandLaunchX

BrandLaunchX introduces Launch Impact Navigation and Orchestration: an AI-first approach that replaces retrospective dashboards with predictive intelligence. Rather than reporting on what has already gone wrong, the platform identifies emerging risks weeks in advance, models remediation options with resource and cost implications, and gives commercial, medical affairs, market access and executive teams a live, connected view of the launch. Early modelling indicates the potential for launches to reach market up to 20% faster while reducing costs by up to 30%.

The company has secured client contracts with enterprise pharmaceutical organisations and is backed by Microsoft for Startups. BrandLaunchX is a ConformanceX Ltd innovation, headquartered in the UK.

More on TelAve News

• Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
• Make America French Again Launches National Campaign
• RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
• 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
• Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area

The BrandLaunchX World Premiere takes place online on May 12, 2026 at 4:00pm BST: a live platform demonstration, independent expert keynote and Q&A with the leadership team.

Register to attend: https://brandlaunchx.com/launch-event

About BrandLaunchX

BrandLaunchX is an AI-powered Launch Impact Navigator built to help biotechnology and pharmaceutical companies bring new therapies to patients faster and more reliably. Founded by former AstraZeneca and Novartis executive Abhijit Sengupta, the platform addresses the coordination failures that cause 80% of drug launches to underperform. BrandLaunchX is a ConformanceX Ltd innovation. https://brandlaunchx.com